Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
Open Access
- 13 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 54 (12), 2978-2986
- https://doi.org/10.1007/s00125-011-2325-z
Abstract
The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI). We examined the effects of olmesartan, an ARB, on primary composite outcome of doubling of serum creatinine, endstage renal disease and death in type 2 diabetic patients with overt nephropathy. Secondary outcome included composite cardiovascular outcomes, changes in renal function and proteinuria. Randomisation and allocation to trial group were carried out by a central computer system. Participants, caregivers, the people carrying out examinations and people assessing the outcomes were blinded to group assignment. Five hundred and seventy-seven (377 Japanese, 200 Chinese) patients treated with antihypertensive therapy (73.5% [n = 424] received concomitant ACEI), were given either once-daily olmesartan (10–40 mg) (n = 288) or placebo (n = 289) over 3.2 ± 0.6 years (mean±SD). In the olmesartan group, 116 developed the primary outcome (41.1%) compared with 129 (45.4%) in the placebo group (HR 0.97, 95% CI 0.75, 1.24; p = 0.791). Olmesartan significantly decreased blood pressure, proteinuria and rate of change of reciprocal serum creatinine. Cardiovascular death was higher in the olmesartan group than the placebo group (ten vs three cases), whereas major adverse cardiovascular events (cardiovascular death plus non-fatal stroke and myocardial infarction) and all-cause death were similar between the two groups (major adverse cardiovascular events 18 vs 21 cases, all-cause deaths; 19 vs 20 cases). Hyperkalaemia was more frequent in the olmesartan group than the placebo group (9.2% vs 5.3%). Olmesartan was well tolerated but did not improve renal outcome on top of ACEI. Trial registration: ClinicalTrials.gov NCT00141453 Funding: The ORIENT study was supported by a research grant from Daiichi Sankyo.This publication has 25 references indexed in Scilit:
- Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?Diabetic Medicine, 2008
- Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 DiabetesDiabetes Care, 2007
- Reduction of Microalbuminuria in Patients With Type 2 DiabetesDiabetes Care, 2007
- Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL studyClinical and Experimental Nephrology, 2006
- Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicineBMJ, 2006
- Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study DesignHypertension Research, 2006
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureThe New England Journal of Medicine, 2001
- Global and societal implications of the diabetes epidemicNature, 2001
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)Journal of the Renin-Angiotensin-Aldosterone System, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958